As evidenced by the published CMS Open Payments data, it is clear that 2021 brought unique challenges and new business processes for life sciences organizations. Understanding how spend changed last year is important; it provides a window into how policies may have changed and how they will continue to evolve in 2023.
Listen as MediSpend’s Director of Compliance Solutions, Lauren Howe, and MediSpend’s Director of Product Management, Bryan Stinehour, analyze the 2021 CMS Open Payments data and provide insights into the data trends for 2022 and beyond.
About MediSpend
MediSpend is a global technology company providing best-in-class solutions that enable life science companies to compliantly manage high-risk business functions through top-rated software and client services. MediSpend is the compliance system of record for some of the world’s largest pharmaceutical, medical device, dental and emerging biotech companies around the world. The MediSpend Global Compliance Suite represents the industry’s first global SaaS solution purpose-built to manage the end-to-end process of HCP engagement through transparency reporting, which includes software that facilitates external grant requests. MediSpend is headquartered in Portsmouth, N.H., with offices in Minnesota, New York, Pennsylvania and the Netherlands.